References in periodicals archive ?
The study assessed 465 patients from a previous Eastern Cooperative Oncology Group (ECOG) study with hormone receptor-positive breast cancer, who had zero to three positive or negative axillary lymph nodes and received contemporary chemohormonal therapy.
Another participant said that she knew she had a very low risk for recurrence because her lumpectomy had been 10 years ago, she had negative axillary lymph nodes, and her tumor was negative for estrogen receptors.
For patients with low-risk disease (small tumors, negative axillary lymph nodes, estrogen receptor-positive), this is typically followed by five years of tamoxifen treatment.